JAMP Fingolimod

Reference product GILENYA®







Therapeutic use	Sphingosine 1-phosphate receptor modulator		
Indication ¹	JAMP Fingolimod is indicated as: - monotherapy for the treatment of patients with the relapsing-remitting form of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the progression of physical disability. JAMP FINGOLIMOD is generally recommended in MS patients who have had an inadequate response to, or are unable to tolerate, one or more therapies for multiple sclerosis. † JAMP Fingolimod should only be prescribed by neurologists who are experienced in the treatment of multiple sclerosis, and are knowledgeable of the efficacy and safety profile of JAMP Fingolimod and are able to discuss benefits/risks with patients.		
Active ingredient	Fingolimod hydrochloride		
Dosage strength	0.5 mg		
DIN	02487772		
Supplied	3 x 10 count blister packs		
Storage conditions	Store at 15°C to 25°C; protect from moisture.		
Shelf life	24 M		

Consult the Product Monograph at www.jampinfo.com for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-866-399-9091 Option 2.

This document contains information only for residents of Canada. Please be aware that JAMP PHARMA CORPORATION assumes no responsibility for access to and use of such information which may not comply with legal restrictions, regulations, registrations or intended use in the country if your origin. Eligibility restrictions and other terms and conditions may apply.

Reference: 1. JAMP Fingolimod Product Monograph. JAMP Pharma Corporation, January 11, 2022.







FOR YOUR PATIENTS WITH RELAPSING-REMITTING FORM OF MULTIPLE SCLEROSIS (MS):

• AS MONOTHERAPY TO REDUCE THE FREQUENCY OF CLINICAL EXACERBATIONS AND TO DELAY THE PROGRESSION OF PHYSICAL DISABILITY. JAMP FINGOLIMOD IS GENERALLY RECOMMENDED IN MS PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO, OR ARE UNABLE TO TOLERATE, ONE OR MORE THERAPIES FOR MS†

The JAMP Care™ Patient Support Program

Provides the following benefits to your patients taking JAMP Fingolimod



Multiple Sclerosis certified nurse as single point of contact

Call toll-free: **1-855-310-5102** Monday to Friday, 8am to 8pm EST † JAMP Fingolimod should only be prescribed by neurologists who are experienced in the treatment of multiple sclerosis, and are knowledgeable of the efficacy and safety profile of JAMP Fingolimod and are able to discuss benefits/risks with patients.



Reimbursement navigation



Bridging(as per provincial regulations)



Financial assistance (as per provincial regulations)



Coverage renewal 3 months in advance



First dose observation





Personalized consultation with a nutritionist (available on demand)

JAMP Fingolimod	JAMP Care™	Other Programs†
MS-certified nurse as single point of contact	✓	
Reimbursement navigation	✓	✓
Bridging	✓	✓
Financial assistance	✓	✓
Coverage renewal 3 months in advance	✓	
Blood/laboratory work & coordination	✓	
Lab work/accelerated elimination procedure	✓	✓
Personalized consultation with nutritionist (available on demand)	✓	
Patient education materials	✓	✓
First dose observation	✓	

^{*} Terms and conditions apply

For more information on the JAMP Care Patient Support Program



Call toll-free: 1-855-310-5102

Fax: **1-888-331-3432**

Monday to Friday, 8am to 8pm EST



Email: jampcare@supportprogram.com




For specific questions

about JAMP Fingolimod

Call the JAMP Pharma Group Medical Information Department at 1-866-399-9091 Option 2



Email: medinfo@jamppharma.com



Consult the Product Monograph at **www.jampinfo.com** for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-866-399-9091 Option 2.

Reference: 1. JAMP Fingolimod Product Monograph. JAMP Pharma Corporation, January 11, 2022.





[†]Based on public data relating to patient assistance programs available in Canada as of December 20, 2022.